Fatigue News and Research

RSS

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Intermediate anti-tTG levels affects birth outcomes, new study reveals

Pregnant women with mid to high levels of antibodies common in patients with celiac disease are at risk for having babies with reduced fetal weight and birth weight, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

30 Apr 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed a therapy for pancreatic cancer that uses Listeria bacteria to selectively infect tumor cells and deliver radioisotopes into them.

25 Apr 2013

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia.

25 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Johns Hopkins study finds that medical interns spend just 12% of time with patients

Medical interns spend just 12 percent of their time examining and talking with patients, and more than 40 percent of their time behind a computer, according to a new Johns Hopkins study that closely followed first-year residents at Baltimore's two large academic medical centers.

24 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Oncology nurses explore how to better combat patient fatigue

They are key members of the healthcare team who face ongoing challenges on how best to provide optimum care to patients affected by cancer. Oncology nurses at The Cancer Institute of New Jersey continually strive to improve patient care and have recently explored how to better combat patient fatigue, the importance of documenting sleep-wake disturbances and the development of a toolkit to help patients better follow their oral treatment schedule during clinical trials.

23 Apr 2013

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Afghanistan's geography is dominated by a collection of craggy peaks, the highest-a mountain known as Noshaq-has been measured to 7,492 meters. Consequently, the soldiers on duty in this mountainous terrain must often ascend to great heights as part of their duty.

22 Apr 2013

Study shows association between physical activity, reduced mortality among breast cancer survivors

Breast cancer survivors are among the women who could most benefit from regular physical activity, yet few meet national exercise recommendations during the 10 years after being diagnosed, according to a study by researchers at Fred Hutchinson Cancer Research Center.

18 Apr 2013

First Edition: April 16, 2013

Today's headlines include coverage of the Supreme Court oral arguments regarding whether patents should be granted for human genes.

16 Apr 2013

Study shows driver fatigue causes 20% of road crashes

A 100-car naturalistic driving study conducted by the Virginia Tech Transportation Institute has shown that fatigue is a cause of 20 percent of crashes, rather than the 2 or 3 percent previously estimated based on surveys, simulator studies, and test tracks.

16 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Michigan's first cardio-oncology clinic launched to prevent heart problems

As cancer therapy becomes more effective and the number of cancer survivors increases, doctors are faced with a new challenge: ensuring patients have a healthy heart to enjoy the rest of their lives.

16 Apr 2013

Cholera epidemic in Haiti expected to worsen with onset of rainy season, lack of funds

"Nearly 2.5 years after it began, Haiti's cholera epidemic is getting worse, not better, and efforts to treat the sick are desperately short of funds, say aid groups on the ground," The Lancet reports.

15 Apr 2013

NTU scientists develop new stroke rehabilitation device

Scientists from Nanyang Technological University have developed a new stroke rehabilitation device which greatly improves recovery in stroke patients.

12 Apr 2013

Manchester study gives full picture of falls in people with rheumatoid arthritis

One in three people with rheumatoid arthritis, regardless of their age, will fall once or more times a year, according to a new University of Manchester study.

12 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

Fatigue News and Research

Study: Biologic response modifying drugs can cause acute liver injury

Intermediate anti-tTG levels affects birth outcomes, new study reveals

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Novel approach using Listeria bacteria shows promise against metastatic pancreatic cancer

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Johns Hopkins study finds that medical interns spend just 12% of time with patients

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Oncology nurses explore how to better combat patient fatigue

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Study shows association between physical activity, reduced mortality among breast cancer survivors

First Edition: April 16, 2013

Study shows driver fatigue causes 20% of road crashes

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Michigan's first cardio-oncology clinic launched to prevent heart problems

Cholera epidemic in Haiti expected to worsen with onset of rainy season, lack of funds

NTU scientists develop new stroke rehabilitation device

Manchester study gives full picture of falls in people with rheumatoid arthritis

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News